138 related articles for article (PubMed ID: 30802549)
1. Investigation of the formation of drug-drug cocrystals and coamorphous systems of the antidiabetic drug gliclazide.
Aljohani M; MacFhionnghaile P; McArdle P; Erxleben A
Int J Pharm; 2019 Apr; 561():35-42. PubMed ID: 30802549
[TBL] [Abstract][Full Text] [Related]
2. Dual-drug amorphous formulation of gliclazide.
Aljohani M; McArdle P; Erxleben A
Drug Dev Ind Pharm; 2021 Feb; 47(2):302-307. PubMed ID: 33492999
[TBL] [Abstract][Full Text] [Related]
3. The natural bile acid surfactant sodium taurocholate (NaTC) as a coformer in coamorphous systems: Enhanced physical stability and dissolution behavior of coamorphous drug-NaTc systems.
Gniado K; MacFhionnghaile P; McArdle P; Erxleben A
Int J Pharm; 2018 Jan; 535(1-2):132-139. PubMed ID: 29107615
[TBL] [Abstract][Full Text] [Related]
4. Formation Mechanism of Coamorphous Drug-Amino Acid Mixtures.
Jensen KT; Larsen FH; Cornett C; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2015 Jul; 12(7):2484-92. PubMed ID: 26057950
[TBL] [Abstract][Full Text] [Related]
5. Formulation, Characterization and In-vitro Evaluation of Fast Dissolv ing Tablets Containing Gliclazide Hydrotropic Solid Dispersions.
Madan JR; Kamate VJ; Awasthi R; Dua K
Recent Pat Drug Deliv Formul; 2017; 11(2):147-154. PubMed ID: 28460615
[TBL] [Abstract][Full Text] [Related]
6. Improving the Solubility, Dissolution, and Bioavailability of Ibrutinib by Preparing It in a Coamorphous State With Saccharin.
Shi X; Song S; Ding Z; Fan B; Huang W; Xu T
J Pharm Sci; 2019 Sep; 108(9):3020-3028. PubMed ID: 31067482
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of Complexation into a Coamorphous System Dramatically Enhances Dissolution and Eliminates Gelation of Amorphous Lurasidone Hydrochloride.
Heng W; Su M; Cheng H; Shen P; Liang S; Zhang L; Wei Y; Gao Y; Zhang J; Qian S
Mol Pharm; 2020 Jan; 17(1):84-97. PubMed ID: 31794225
[TBL] [Abstract][Full Text] [Related]
8. Optimization of gliclazide loaded alginate-gelatin beads employing central composite design.
Elsayed EW; El-Ashmawy AA; Mursi NM; Emara LH
Drug Dev Ind Pharm; 2019 Dec; 45(12):1959-1972. PubMed ID: 31692384
[No Abstract] [Full Text] [Related]
9. Development of a Dissolution Method for Gliclazide Modified-Release Tablets Using USP Apparatus 3 with in Vitro-in Vivo Correlation.
Bezerra KC; Pinto EC; Cabral LM; de Sousa VP
Chem Pharm Bull (Tokyo); 2018; 66(7):701-707. PubMed ID: 29962453
[TBL] [Abstract][Full Text] [Related]
10. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
11. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
12. Amorphous-based controlled-release gliclazide matrix system.
Lu Z; Yang Y; Covington RA; Bi YV; Dürig T; Fassihi R
AAPS PharmSciTech; 2017 Jul; 18(5):1699-1709. PubMed ID: 27714702
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular Cocrystals of Gliclazide: Synthesis, Characterization and Evaluation.
Chadha R; Rani D; Goyal P
Pharm Res; 2017 Mar; 34(3):552-563. PubMed ID: 28035627
[TBL] [Abstract][Full Text] [Related]
14. Coamorphous Active Pharmaceutical Ingredient-Small Molecule Mixtures: Considerations in the Choice of Coformers for Enhancing Dissolution and Oral Bioavailability.
Newman A; Reutzel-Edens SM; Zografi G
J Pharm Sci; 2018 Jan; 107(1):5-17. PubMed ID: 28989014
[TBL] [Abstract][Full Text] [Related]
15. Formulation, Pharmacokinetics evaluation, and IVIVC Assessment of Gliclazide Multiparticulates in Rat Model.
El-Ashmawy AA; Abdou AR; Taha NF; Elsayed EW; Mahmoud KM; Emara LH
AAPS PharmSciTech; 2021 Apr; 22(4):146. PubMed ID: 33929614
[TBL] [Abstract][Full Text] [Related]
16. Indomethacin-omeprazole as therapeutic hybrids? Salt and co-amorphous systems enhancing physicochemical and pharmacological properties.
Nascimento ALCS; Martins ICB; Spósito L; Morais-Silva G; Duarte JL; Rades T; Chorilli M
Int J Pharm; 2024 Mar; 653():123857. PubMed ID: 38281693
[TBL] [Abstract][Full Text] [Related]
17. Design and development of gliclazide-loaded chitosan for oral sustained drug delivery: in vitro/in vivo evaluation.
Barakat NS; Almurshedi AS
J Microencapsul; 2011; 28(2):122-33. PubMed ID: 21110773
[TBL] [Abstract][Full Text] [Related]
18. Drug-Drug Multicomponent Solid Forms: Cocrystal, Coamorphous and Eutectic of Three Poorly Soluble Antihypertensive Drugs Using Mechanochemical Approach.
Haneef J; Chadha R
AAPS PharmSciTech; 2017 Aug; 18(6):2279-2290. PubMed ID: 28101724
[TBL] [Abstract][Full Text] [Related]
19. Coamorphous repaglinide-saccharin with enhanced dissolution.
Gao Y; Liao J; Qi X; Zhang J
Int J Pharm; 2013 Jun; 450(1-2):290-5. PubMed ID: 23612357
[TBL] [Abstract][Full Text] [Related]
20. Effect of two hydrophobic polymers on the release of gliclazide from their matrix tablets.
Hussain T; Saeed T; Mumtaz AM; Javaid Z; Abbas K; Awais A; Idrees HA
Acta Pol Pharm; 2013; 70(4):749-57. PubMed ID: 23923399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
